| Time horizon |
Lifetime |
— |
| Discount rate |
4% |
Perelman et al[@161316] |
| Payer perspective |
NHS of Portugal |
— |
| Willingness-to-pay threshold |
€30 000 |
Perelman et al,[@161316] NICE[@161333] |
| Population dataa |
|
|
| Starting age, y |
69.37 |
Timóteo et al,[@161342] Santos et al[@161343] |
| Male, % |
61.8 |
Timóteo et al,[@161342] Santos et al[@161343] |
| Smokers, % |
17.4 |
Timóteo et al,[@161342] Santos et al[@161343] |
| Diabetes, % |
27.8 |
Timóteo et al,[@161342] Santos et al[@161343] |
| Atrial fibrillation, % |
13.2 |
Timóteo et al,[@161342] Santos et al[@161343] |
| Left ventricular hypertrophy, % |
6.2 |
Assumed equal to HF % from Castellano et al,[@161297] Santos et al[@161343] |
| Systolic blood pressure, mm Hg |
145.1 |
Ferreira,[@161344] Heuschmann et al[@161345] |
| Total cholesterol, mg/dL |
190.8 |
Ferreira,[@161344] Heuschmann et al[@161345] |
| HDL-cholesterol, mg/dL |
45.2 |
Ferreira,[@161344] Heuschmann et al[@161345] |
| hs-CRP, mg/dL |
2.2 |
Dorresteijn et al[@161319] |
| eGFR, ml/min/1.73m2 |
74.3 |
Timóteo et al,[@161346] Dorresteijn et al[@161319] |
| History of abdominal aortic aneurysm, % |
2.1 |
Castro-Ferreira et al[@161347] |
| History of peripheral arterial disease, % |
3.2 |
Timóteo et al[@161348] Santos et al[@161343] |
| Polypill effectiveness |
|
|
| SBP reduction, mm Hg |
1.80 |
NEPTUNO, cohort 2[@161337] |
| TC reduction, mg/dL |
5.28 |
NEPTUNO, cohort 2[@161337] |
| HDL-c increment, mg/dL |
4.01 |
NEPTUNO, cohort 2[@161337] |
| Health utilities |
|
|
| Chronic CHD |
0.84 |
Ara et a[@161329] |
| Chronic stroke |
0.69 |
Ara et a[@161329] |
| Acute CHD |
0.76 |
Ara et a[@161329] |
| Acute stroke |
0.63 |
Ara et al[@161329] |
| Death |
0.00 |
Assumption |
| Drug costs (€) |
|
|
| Annual reimbursement cost—polypillb |
84.62 |
Calculated based on Infarmed drug database |
| Annual reimbursement cost—monotherapies |
63.44 |
Calculated based on Infarmed drug database |
| CV event management costs (€) |
|
|
| Cost of acute CV event (nonfatal) |
4560.1 |
Costa et al[@161327] |
| Cost of acute CV event (fatal) |
3153.5 |
Silva Miguel and Ferreira[@161328] |
| Cost of acute stroke (nonfatal) |
8653.3 |
Costa et al[@161327] |
| Cost of acute stroke (fatal) |
6381.2 |
Costa et al[@161327] |
| Annual cost post-CV event |
643.3 |
Costa et al[@161327] |
| Annual cost post-stroke |
534.8 |
Costa et al[@161327] |
| SMART 10-y CV risk |
|
|
| S0(t=10), adjusted to the cycle length assuming a constant rate over the 1 y and lifetime periods |
0.8107 |
Dorresteijn et al[@161319] |